Brain Research
August 1, 1975
M. Da Prada, A. Saner, W.p. Burkard et al.
71 citations
Lysergic acid diethylamide (LSD) stimulates dopamine receptors in the central nervous system, which may contribute to LSD-induced psychosis. In rats, LSD decreased striatal and retinal homovanillic acid levels without changing dopamine levels, but delayed the disappearance of dopamine after a-methyl-p-tyrosine treatment. In cats, LSD reduced dopamine output into the caudate nucleus perfusate. Additionally, LSD increased adenylate cyclase activity in rat striatal homogenates. These findings suggest that dopamine receptor stimulation is involved in the effects of LSD.
British Journal of Pharmacology
April 1, 1979
Martin Graf, A. Pletscher
45 citations
In rabbit blood platelets, tryptamine, serotonin (5-HT), and related compounds like quipazine and mescaline caused a shape change, which was blocked by low concentrations of methysergide. The most potent blockers of the serotonin-induced shape change were ergoline derivatives and neuroleptic drugs, showing high stereoselectivity. LSD, psilocine, and some dimethylated tryptamines acted as mixed agonist-antagonists. Compounds that were agonists or mixed agonist-antagonists on platelets also act as serotonin agonists in the central nervous system. However, platelet serotonin receptors responded differently to antagonists than those in brain areas with dense serotonin innervation, but similarly to receptors in spinal cord, cerebral cortex, and reticular formation. Platelets may serve as cautious models for some, but not all, central serotonin receptors.